Effect of traditional Chinese medicine on portal vein thrombosis in patients with liver cirrhosis and its medication characteristics

Yanan GUO; Hongtu GU; Changqing ZHAO; Yongping MU; Jili YUAN; Feng XING; Yanyan TAO; Jing LYU; Chenghai LIU

doi:10.3969/j.issn.1001-5256.2023.02.014

Volume 39 Issue 2

Feb. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(2): 345-351

PDF( 2209 KB)

Effect of traditional Chinese medicine on portal vein thrombosis in patients with liver cirrhosis and its medication characteristics

DOI: 10.3969/j.issn.1001-5256.2023.02.014

Yanan GUO¹,
Hongtu GU^{1, 2},
Changqing ZHAO^{1, 2},
Yongping MU^{1, 2},
Jili YUAN^{1, 2},
Feng XING^{1, 2},
Yanyan TAO^{1, 2},
Jing LYU^{1, 2
,
,
,},
Chenghai LIU^{1, 2, 3
,
,
,}

1.
Second Department of Hepatology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine; Institute of Liver Diseases, Shanghai Institute of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Shanghai 201203, China
3.
Key Laboratory of Liver and Kidney Diseases, Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81603467);

Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation Capability of Municipal Hospitals in Shanghai· Clinical Skill Improvement Project for Major Diseases (16CR1026B)

More Information

Corresponding author: LYU Jing, ljliver@163.com (ORCID: 0000-0002-7577-0419); LIU Chenghai, chenghailiu@hotmail.com (ORCID: 0000-0002-1696-6008)
Received Date: 2022-09-15
Accepted Date: 2022-10-19
Published Date: 2023-02-20

Abstract

Abstract

Objective To investigate the therapeutic effect of traditional Chinese medicine (TCM) on portal vein thrombosis (PVT) in patients with liver cirrhosis and its medication characteristics. Methods A retrospective analysis was performed for 89 patients with liver cirrhosis and PVT who were hospitalized and treated in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, and according to whether TCM treatment was applied in combination, they were divided into TCM group with 59 patients and control group with 30 patients. Related data were collected for the two groups, including demographic data, laboratory examination, radiological examination, gastroscopy, history of surgery, portal hypertension-related complications, medication, and follow-up data. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between two groups. An ordinal polytomous Logistic regression analysis was used for multivariate analysis. TCM Inheritance Computing Platform (V3.0) was used to perform a drug effect cluster analysis of TCM prescriptions. Results The multivariate logistic regression analysis showed that esophageal and gastric varices (odds ratio [OR]=3.144, 95% confidence interval [CI]: 1.221-8.094), PVT involving the portal vein (PV) and the superior mesenteric vein (SMV) (OR=51.667, 95%CI: 3.536-754.859), PVT involving PV+spleen vein (SV)+SMV (OR=13.271, 95% CI: 2.290-76.928), cavernous transformation of the portal vein (OR=11.896, 95%CI: 1.172-120.696), and TCM intervention (OR=0.348, 95%CI: 0.129-0.938) were influencing factors for the outcome of PVT in liver cirrhosis. Follow-up results showed that compared with the control group, the TCM group had a significantly lower progression rate (16.95% vs 56.67%, P < 0.001) and a significantly lower incidence rate of variceal rupture and bleeding (8.47% vs 33.33%, P < 0.001). Effective TCM drugs with a relatively high frequency of use included deficiency-tonifying drugs (359 times, 34.6%), blood-activating and stasis-resolving drugs (202 times, 19.5%), and diuresis-inducing and dampness-draining drugs (180 times, 17.3%); the TCM drugs with a relatively high frequency of use included Astragalus membranaceus (57 times, 8.7%), Angelica sinensis (50 times, 7.6%), and leech (48 times, 7.3%); TCM drug combinations with a relatively high frequency of use included Astragalus membranaceus+Angelica sinensis, Astragalus membranaceus+leech, Angelica sinensis+leech, and Astragalus membranaceus+Angelica sinensis+leech. Conclusion Qi-tonifying, blood-activating, and stasis-breaking drugs, such as Astragalus membranaceus, Angelica sinensis, and leech, can promote the stabilization or recanalization of PVT in liver cirrhosis and reduce the incidence rate of bleeding events due to portal hypertension.
- Liver Cirrhosis,
- Portal Vein Thrombosis,
- Pathogenests (TCM)

FullText(HTML)

References(15)

References

[1]	SENZOLO M, GARCIA-TSAO G, GARCÍA-PAGÁN JC. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021, 75(2): 442-453. DOI: 10.1016/j.jhep.2021.04.029.
[2]	STINE JG, SHAH PM, CORNELLA SL, et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis[J]. World J Hepatol, 2015, 7(27): 2774-2780. DOI: 10.4254/wjh.v7.i27.2774.
[3]	QI X, SU C, REN W, et al. Association between portal vein thrombosis and risk of bleeding in liver cirrhosis: A systematic review of the literature[J]. Clin Res Hepatol Gastroenterol, 2015, 39(6): 683-691. DOI: 10.1016/j.clinre.2015.02.012.
[4]	INTAGLIATA NM, CALDWELL SH, TRIPODI A. Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis[J]. Gastroenterology, 2019, 156(6): 1582-1599. e1. DOI: 10.1053/j.gastro.2019.01.265.
[5]	MANCUSO A. Controversies in the management of portal vein thrombosis in liver cirrhosis[J]. J Clin Med, 2020, 9(12): 3916. DOI: 10.3390/jcm9123916.
[6]	LYU J, DONG SS, GU HT, et al. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. J Clin Hepatol, 2019, 35(10): 2210-2213. DOI: 10.3969/j.issn.1001-5256.2019.10.016. 吕靖, 董思思, 顾宏图, 等. 肝硬化并发门静脉血栓的危险因素及中医证候特点[J]. 临床肝胆病杂志, 2019, 35(10): 2210-2213. DOI: 10.3969/j.issn.1001-5256.2019.10.016.
[7]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[8]	Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai)[J]. J Clin Hepatol, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007. 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36(12): 2667-2674. DOI: 10.3969/j.issn.1001-5256.2020.12.007.
[9]	Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China[M]. Beijing: China Medical Science Press, 2015. 国家药典委员会. 中国药典[M]. 北京: 中国医药科技出版社, 2015.
[10]	NERY F, CHEVRET S, CONDAT B, et al. Causes and consequences of portal vein thrombosis in 1, 243 patients with cirrhosis: results of a longitudinal study[J]. Hepatology, 2015, 61(2): 660-667. DOI: 10.1002/hep.27546.
[11]	AHMED Z, SINGAL AK, KAMATH PS. Anticoagulants and their monitoring[J]. Clin Liver Dis (Hoboken), 2020, 16(4): 146-148. DOI: 10.1002/cld.946.
[12]	GE L, ZHOU L. Effect of Huangqi Zezhu Danshen decoction and enoxaparin injection on liver cirrhosis complicated with portal vein thrombosis and its influence on coagulation function[J]. Chin J Thromb Hemost, 2021, 27(5): 742-743, 746. DOI: 10.3969/j.issn.1009-6213.2021.05.008. 葛莉, 周蕾. 黄芪莪术丹参汤与依诺肝素注射液治疗肝硬化合并门静脉血栓形成的疗效及对凝血功能的影响[J]. 血栓与止血学, 2021, 27(5): 742-743, 746. DOI: 10.3969/j.issn.1009-6213.2021.05.008.
[13]	LI SX, XIONG JH, CAO JB. One case report of Anluo Huaxian pill in treatment of portal vein thrombosis of liver cirrhosis[J]. Beijing Med J, 2015, 37(3): 303-304. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201503044.htm 李绍祥, 熊锦华, 曹建彪. 安络化纤丸治疗肝硬化门静脉血栓1例报告[J]. 北京医学, 2015, 37(3): 303-304. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201503044.htm
[14]	RODRIGUEZ-CASTRO KI, VITALE A, FADIN M, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis[J]. Eur J Gastroenterol Hepatol, 2019, 31(1): 34-42. DOI: 10.1097/MEG.0000000000001237.
[15]	LV Y, BAI W, LI K, et al. Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: A prospective observational study[J]. Am J Gastroenterol, 2021, 116(7): 1447-1464. DOI: 10.14309/ajg.0000000000001194.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (809) PDF downloads(80)

Effect of traditional Chinese medicine on portal vein thrombosis in patients with liver cirrhosis and its medication characteristics

DOI: 10.3969/j.issn.1001-5256.2023.02.014

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content